Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luspatercept (Primary)
Indications Beta-thalassaemia
Focus Adverse reactions
Sponsors Acceleron Pharma

Most Recent Events

17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
17 Jun 2021 Results analyzing MCV variation as an early predictor of response to Luspatercept by using data from phase II/III clinical trials (NCT01749540, NCT02268409, NCT02604433, NCT03342404, NCT04064060) presented at the 26th Congress of the European Haematology Association
13 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com